 BOSTON, Aug. 30, 2022 GLOBE NEWSWIRE -- Entrada Therapeutics, Inc. Nasdaq: TRDA, a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle EEVTM therapeutics as a new class of medicines, today announced that Nathan Dowden, Chief Operating Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 14, 2022. 